Your browser doesn't support javascript.
loading
Meloxicam and/or Etoricoxib Could Be Administered Safely in Two Equal Doses during an Open Oral Challenge in Patients with Nonsteroidal Anti-Inflammatory Drug Hypersensitivity.
Rojas-Mejía, Dolly Vanessa; Silva Espinosa, Diana Lucía; Martínez, Diana Marcela; Ramírez Zuluaga, Luis Fernando; Serrano Reyes, Carlos Daniel.
Afiliação
  • Rojas-Mejía DV; Allergy Unit, Fundación Valle De Lili, Cali, Colombia.
  • Silva Espinosa DL; Allergy Unit, Fundación Valle De Lili, Cali, Colombia.
  • Martínez DM; Allergy Unit, Fundación Valle De Lili, Cali, Colombia.
  • Ramírez Zuluaga LF; Allergy Unit, Fundación Valle De Lili, Cali, Colombia.
  • Serrano Reyes CD; Allergy Unit, Fundación Valle De Lili, Cali, Colombia, carlos.serrano@fvl.org.co.
Int Arch Allergy Immunol ; 182(5): 433-439, 2021.
Article em En | MEDLINE | ID: mdl-33592604
BACKGROUND: Hypersensitivity reactions to nonsteroidal anti-inflammatory drugs (NSAIDs) are common. These patients require an effective and safe analgesic alternative. OBJECTIVE: The aim of the study was to demonstrate the safety of meloxicam and etoricoxib administered by open oral challenge in 2 equal steps in patients with NSAID hypersensitivity. METHODS: A cross-sectional, descriptive study of patients with a diagnosis of NSAID hypersensitivity who underwent an oral drug provocation test (DPT) with meloxicam or etoricoxib between January 2011 and August 2017 was conducted. The analysis was performed from a database in BD Clinic. RESULTS: Two hundred and twenty-eight oral provocations were performed with an alternative NSAID (203 with meloxicam and 25 with etoricoxib) in 217 patients with hypersensitivity to NSAIDs. The median age was 38 years. Ninety-eight percent of meloxicam and 100% of etoricoxib DPTs were performed in 2 steps (without previous placebo), and 52% and 64% of meloxicam and etoricoxib DPTs, respectively, were performed with 50% of the therapeutic dose in each step. Tolerance to meloxicam was demonstrated in 192 patients (94.5%) and in 100% of patients receiving etoricoxib. CONCLUSIONS: Open oral provocation with meloxicam and etoricoxib carried out in 2 steps without placebo seems to be safe and implies less costs and less time expenditure. Also, it could be performed with 2 equal doses.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anti-Inflamatórios não Esteroides / Hipersensibilidade a Drogas / Inibidores de Ciclo-Oxigenase 2 / Substituição de Medicamentos / Meloxicam / Etoricoxib Tipo de estudo: Clinical_trials / Diagnostic_studies Limite: Humans Idioma: En Revista: Int Arch Allergy Immunol Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anti-Inflamatórios não Esteroides / Hipersensibilidade a Drogas / Inibidores de Ciclo-Oxigenase 2 / Substituição de Medicamentos / Meloxicam / Etoricoxib Tipo de estudo: Clinical_trials / Diagnostic_studies Limite: Humans Idioma: En Revista: Int Arch Allergy Immunol Ano de publicação: 2021 Tipo de documento: Article